Furthermore, Epix has completed enrollment of its Phase IIa clinical trial of PRX-03140 in Alzheimer’s disease and reaffirmed that it is on track to announce the findings of this study by the end of 2007.
PRX-00023 (highly selective 5-HT1A partial agonist)and PRX-03140 (selective for the 5-HT4 receptor in the brain) were discovered by using the company’s proprietary G-Protein Coupled Receptors (GPCR) modeling, screening and lead optimization technology, Epix said.
Michael Kauffman, CEO of Epix, said: “We are very pleased to achieve these significant milestones for these two important clinical trials. We believe that the rapid pace at which we were able to recruit patients into the phase IIb major depressive disorder trial is indicative of the interest in, and need for, new and improved treatments for depression.”